A Review of Malignancies Observed during Efalizumab (Raptiva®) Clinical Trials for Plaque Psoriasis

Publisher： Karger

E-ISSN： 1421-9832|213|3|204-214

ISSN： 1018-8665

Source： Dermatology, Vol.213, Iss.3, 2006-10, pp. : 204-214

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

T-Cell Modulation for the Treatment of Chronic Plaque Psoriasis with Efalizumab (Raptiva™): Mechanisms of Action

By  

Dermatology, Vol. 208, Iss. 4, 2004-06 ,pp. : 297-306

Karger

Access to resources Recommend Favorite

Patients with Moderate to Severe Plaque Psoriasis: One Year after the European Medicines Agency Recommendation of Efalizumab Suspension

By  

Dermatology, Vol. 222, Iss. 3, 2011-04 ,pp. : 250-255

Karger

Access to resources Recommend Favorite

Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 Patients

By  

Dermatology, Vol. 232, Iss. 6, 2017-02 ,pp. : 648-654

Karger

Access to resources Recommend Favorite

Bullous Pemphigoid Occurring during Efalizumab Treatment for Psoriasis: A Paradoxical Auto-Immune Reaction?

By  

Dermatology, Vol. 219, Iss. 1, 2009-03 ,pp. : 89-90

Karger

Access to resources Recommend Favorite

Efficacy of Short-Term Cyclosporine Treatment to Control Psoriasis-Related Events during Efalizumab Therapy

By  

Dermatology, Vol. 218, Iss. 2, 2008-10 ,pp. : 146-150

Karger

Access to resources Recommend Favorite